Provided herein are compounds of the formula (I):
as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
[EN] MODULATORS OF CHEMOKINE RECEPTORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DES CHIMIOKINES
申请人:CHEMOCENTRYX INC
公开号:WO2017087607A1
公开(公告)日:2017-05-26
Compounds are provided as chemokine inhibitors having the structure: Formula (A).
提供的化合物是具有结构的趋化因子抑制剂:化学式(A)。
[EN] INHIBITORS OF CXCR2<br/>[FR] INHIBITEURS DE CXCR2
申请人:CHEMOCENTRYX INC
公开号:WO2017087610A1
公开(公告)日:2017-05-26
Compounds are provided as inhibitors of CXCR2, having the structure (I).
提供作为CXCR2抑制剂的化合物,其结构为(I)。
Compounds and methods for F labelled agents
申请人:Bayer Schering Pharma Aktiengesellschaft
公开号:EP1897885A1
公开(公告)日:2008-03-12
This invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula 11, wherein the substituents G, L, U, and Q have the meaning as defined in the specification.
The present invention relates to novel compounds suitable for or already radiolabeled with
18
F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims.